文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

由前蛋白转化酶枯草杆菌蛋白酶/kexin 9型(PCSK9)功能获得性突变引起的纯合子家族性高胆固醇血症的基因型和表型特征。

Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation.

作者信息

Mabuchi Hiroshi, Nohara Atsushi, Noguchi Tohru, Kobayashi Junji, Kawashiri Masa-aki, Inoue Takeshi, Mori Mika, Tada Hayato, Nakanishi Chiaki, Yagi Kunimasa, Yamagishi Masakazu, Ueda Kousei, Takegoshi Tadayoshi, Miyamoto Susumu, Inazu Akihiro, Koizumi Junji

机构信息

Department of Lipidology, Graduate School of Medical Science, Kanazawa University, Takara-machi 13-1, Kanazawa 920-8640, Japan.

Department of Lipidology, Graduate School of Medical Science, Kanazawa University, Takara-machi 13-1, Kanazawa 920-8640, Japan.

出版信息

Atherosclerosis. 2014 Sep;236(1):54-61. doi: 10.1016/j.atherosclerosis.2014.06.005. Epub 2014 Jun 26.


DOI:10.1016/j.atherosclerosis.2014.06.005
PMID:25014035
Abstract

BACKGROUNDS: Familial hypercholesterolemia (FH) is an autosomal dominant disease characterized by hypercholesterolemia, tendon xanthomas, and premature coronary heart disease. FH is caused by mutations of "FH genes," which include the LDL-receptor (LDLR), apolipoprotein B-100 (APOB) or proprotein convertase subtilisin/kexin type 9 (PCSK9). We evaluated the usefulness of FH gene analysis for diagnosing homozygous FH (homo-FH), particularly in cases caused by gain-of-function (g-o-f) mutations in PCSK9 (PCSK9 E32K). OBJECTIVES: To evaluate the frequency of homo-FH caused by PCSK9 E32K compared with FH due to other genetic causes and to report the phenotypic features of homo-FH caused by PCSK9 E32K. METHODS: Genomic DNA was prepared from white blood cells, and LDLR and PCSK9 mutations were identified using the Invader assay method. RESULTS: Of the 1055 hetero-FH patients, 62 patients (5.9%) carried the PCSK9 E32K mutation, while in the 82 alleles of 41 homo-FH patients, 13 (15.9%) had double mutations of LDLR allele and PCSK9 E32K mutation. Mean plasma total cholesterol (TC) (9.93 ± 2.95 mmol/L, mean ± SD) in true homo-FH cases with PCSK9 E32K or double hetero-FH cases with PCSK9 E32K and LDLR mutations were significantly lower than those in true homo-FH (18.06 ± 4.96 mmol/L) and compound heterozygous cases with LDLR mutations (14.84 ± 1.62 mmol/L). Mean plasma TC concentrations in the 59 hetero-FH cases with PCSK9 E32K (7.21 ± 1.55 mmol/L) were significantly lower than those (8.94 ± 1.53 mmol/L) in the hetero-FH by LDLR mutations. CONCLUSIONS: FH caused by PCSK9 g-o-f mutations is relatively common in Japan and causes a mild type of homo- and hetero-FH compared with FH caused by LDLR mutations.

摘要

背景:家族性高胆固醇血症(FH)是一种常染色体显性疾病,其特征为高胆固醇血症、肌腱黄色瘤和早发性冠心病。FH由“FH基因”的突变引起,这些基因包括低密度脂蛋白受体(LDLR)、载脂蛋白B - 100(APOB)或前蛋白转化酶枯草溶菌素/kexin 9型(PCSK9)。我们评估了FH基因分析在诊断纯合子FH(homo - FH)中的作用,特别是在由PCSK9功能获得性(g - o - f)突变(PCSK9 E32K)引起的病例中。 目的:评估与其他遗传原因导致的FH相比,由PCSK9 E32K引起的homo - FH的发生率,并报告由PCSK9 E32K引起的homo - FH的表型特征。 方法:从白细胞中提取基因组DNA,使用侵入检测法鉴定LDLR和PCSK9突变。 结果:在1055例杂合子FH患者中,62例(5.9%)携带PCSK9 E32K突变,而在41例homo - FH患者的共82个等位基因中,13个(15.9%)具有LDLR等位基因双突变和PCSK9 E32K突变。携带PCSK9 E32K的真正homo - FH病例或同时携带PCSK9 E32K和LDLR突变的双杂合子FH病例的平均血浆总胆固醇(TC)(9.93±2.95 mmol/L,平均值±标准差)显著低于真正的homo - FH(18.06±4.96 mmol/L)和携带LDLR突变的复合杂合子病例(14.84±1.62 mmol/L)。59例携带PCSK9 E32K的杂合子FH病例的平均血浆TC浓度(7.21±1.55 mmol/L)显著低于由LDLR突变引起的杂合子FH病例(8.94±1.53 mmol/L)。 结论:在日本,由PCSK9功能获得性突变引起的FH相对常见,与由LDLR突变引起的FH相比,会导致一种轻度类型的纯合子和杂合子FH。

相似文献

[1]
Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation.

Atherosclerosis. 2014-9

[2]
The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation.

Atherosclerosis. 2009-11-20

[3]
Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan.

Atherosclerosis. 2010-11-13

[4]
Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.

Atherosclerosis. 2016-8-26

[5]
Molecular genetics of familial hypercholesterolemia in Israel-revisited.

Atherosclerosis. 2016-12-18

[6]
Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients.

Atherosclerosis. 2012-2-19

[7]
Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations.

Circ J. 2016

[8]
Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia.

Atherosclerosis. 2006-6

[9]
The contribution of PCSK9 levels to the phenotypic severity of familial hypercholesterolemia is independent of LDL receptor genotype.

Metabolism. 2015-8-20

[10]
Genetic polymorphisms in LDLR, APOB, PCSK9 and other lipid related genes associated with familial hypercholesterolemia in Malaysia.

PLoS One. 2013-4-8

引用本文的文献

[1]
Nonalcoholic Fatty Liver Disease Risk and Proprotein Convertase Subtilisin Kexin 9 in Familial Hypercholesterolemia Under Statin Treatment.

Nutrients. 2024-10-29

[2]
Prevalence and Clinical Characteristics of Familial Hypercholesterolemia in Patients with Acute Coronary Syndrome according to the Current Japanese Guidelines: Insight from the EXPLORE-J study.

J Atheroscler Thromb. 2025-1-1

[3]
Methylation status of , and is associated with cardiovascular events in familial hypercholesterolemia.

Epigenomics. 2024

[4]
Case Series of Genetically Confirmed Index Cases of Familial Hypercholesterolemia in Primary Care.

Am J Case Rep. 2023-4-27

[5]
Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022.

J Atheroscler Thromb. 2023-5-1

[6]
Genetic and molecular architecture of familial hypercholesterolemia.

J Intern Med. 2023-2

[7]
Inclisiran: How Widely and When Should We Use It?

Curr Atheroscler Rep. 2022-10

[8]
LDL-cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid-lowering therapy.

J Clin Lab Anal. 2021-11

[9]
Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia.

J Pers Med. 2021-8-31

[10]
Familial Hypercholesterolemia in Patients with Acute Coronary Syndrome: Genetic Insights from EXPLORE-J.

J Atheroscler Thromb. 2022-8-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索